In addition, LOL treatment markedly enhanced Nrf-2/HO-1/NQO1 signaling with elevated the activities of anti-oxidant enzymes, such as GSH, CAT, and SOD, and suppressed the levels of ROS, NO, and TBARS in lung tissues of the OVA-challenged allergic asthma model. The gene discussed is NFE2L2; the disease is allergic asthma.